Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 0.58 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.49 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.47 |
| ▸ | RET | P07949 | 1/20 | 0.47 |
| ▸ | MET | P08581 | 1/20 | 0.47 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.47 |
| ▸ | TEC | P42680 | 1/20 | 0.47 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.47 |
| ▸ | EPHA4 | P54764 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.47 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.47 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.47 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29834662 | 0.91 | EGFR (0.68) | EGFRERBB2RIPK2RETMET | |
| SCHEMBL29834658 | 0.85 | CNR1 (0.47) | EGFREPHB4 | |
| SCHEMBL28983503 | 0.82 | EGFR (0.61) | EGFRERBB2RIPK2RETMET | |
| SCHEMBL29834686 | 0.79 | ENPP1 (0.52) | EGFRFGFR1 | |
| SCHEMBL21612797 | 0.79 | EGFR (0.69) | EGFRERBB2RIPK2RETMET | |
| SCHEMBL14489807 | 0.78 | ENPP1 (0.55) | EGFRERBB2RIPK2RETMET | |
| SCHEMBL29834627 | 0.76 | NSD2 (0.54) | EGFREPHB4 | |
| SCHEMBL24375728 | 0.76 | EGFR (0.72) | EGFRERBB2RIPK2RETMET | |
| SCHEMBL27148008 | 0.75 | ENPP1 (0.54) | EGFRERBB2RIPK2RETMET | |
| SCHEMBL24714522 | 0.75 | EGFR (0.62) | EGFRERBB2RIPK2RETMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240398805-A1 | QUINAZOLINE DERIVED COMPOUNDS AS EGFR INHIBITORS AND THEIR USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-12-05 | — | — | US | disclosed |
| WO-2022170043-A1 | QUINAZOLINE DERIVED COMPOUNDS AS EGFR INHIBITORS AND THEIR USES THEREOF | ACCUTAR BIOTECHNOLOGY, INC. (US) | 2022-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240398805-A1 | QUINAZOLINE DERIVED COMPOUNDS AS EGFR INHIBITORS AND THEIR USES THEREOF | ERBB2, EGFR, ERBB4 | EGFR 2/4885ERBB2 1/4885RIPK2 1352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.